Centre of Excellence in Severe Asthma and Priority Research Centre for Healthy Lungs, University of Newcastle, Newcastle, NSW, Australia; Department of Respiratory and Sleep Medicine, John Hunter Hospital, Newcastle, NSW, Australia.
Centre of Excellence in Severe Asthma and Priority Research Centre for Healthy Lungs, University of Newcastle, Newcastle, NSW, Australia; Department of Respiratory and Sleep Medicine, John Hunter Hospital, Newcastle, NSW, Australia.
J Allergy Clin Immunol Pract. 2021 Nov;9(11):3868-3875. doi: 10.1016/j.jaip.2021.08.028. Epub 2021 Sep 4.
Pulmonary comorbidities can increase disease severity and health care costs associated with asthma management. Vocal cord dysfunction/inducible laryngeal obstruction is a common comorbidity that results from intermittent laryngeal obstruction. Patients describe distinct episodes of dyspnea that do not respond to bronchodilators. Inspiratory stridor is common. The gold standard diagnostic testing strategy is continuous laryngoscopy performed during exercise or irritant challenges. Dysfunctional breathing (DB) is an overarching term that describes conditions with a chronic change in the pattern of breathing that results in pulmonary and extrapulmonary symptoms. The prevalence of DB in asthma is up to 30%, and breathing retraining can improve symptoms and quality of life in people with DB and asthma. Asthma-chronic obstructive pulmonary disease overlap (ACO) refers to both asthmatics who develop fixed airflow obstruction after a history of exposure to smoke or biomass and patients with chronic obstructive pulmonary disease who have "asthmatic features" such as a large bronchodilator response, elevated levels of serum IgE, or peripheral eosinophil counts ≥300 per μL. Triple inhaler therapy with inhaled corticosteroid/long-acting beta-agonist/long-acting muscarinic should be considered in people with ACO and severe symptoms or frequent exacerbations. The clinical expression of bronchiectasis involves persistent mucus hypersecretion, recurrent exacerbations of infective bronchitis, incompletely reversible airflow obstruction, and lung fibrosis and can occur in up to 30% of adults with longstanding asthma. The treatable traits strategy is a useful model of care to manage the complexity and heterogeneity of asthma with pulmonary comorbidity.
肺部合并症可增加与哮喘管理相关的疾病严重程度和医疗保健费用。声带功能障碍/可诱导性喉阻塞是一种常见的合并症,由间歇性喉阻塞引起。患者描述了不同的呼吸困难发作,对支气管扩张剂没有反应。吸气性喘鸣很常见。金标准诊断测试策略是在运动或刺激物挑战期间进行持续喉镜检查。功能障碍性呼吸(DB)是一个总称,描述了一种慢性呼吸模式改变导致肺和肺外症状的情况。哮喘中 DB 的患病率高达 30%,呼吸训练可以改善 DB 和哮喘患者的症状和生活质量。哮喘-慢性阻塞性肺疾病重叠(ACO)是指有吸烟或生物量暴露史后出现固定气流阻塞的哮喘患者,以及有“哮喘特征”的慢性阻塞性肺疾病患者,如大支气管扩张剂反应、血清 IgE 水平升高或外周血嗜酸性粒细胞计数≥300/μL。对于 ACO 且症状严重或频繁恶化的患者,应考虑三联吸入疗法,包括吸入皮质激素/长效β-激动剂/长效毒蕈碱激动剂。支气管扩张的临床表现包括持续黏液高分泌、复发性感染性支气管炎加重、不完全可逆的气流阻塞以及肺纤维化,在长期哮喘的成年人中高达 30%。可治疗特征策略是一种有用的护理模式,可用于管理具有肺部合并症的哮喘的复杂性和异质性。